ACHNYSEWholesale-Medical, Dental & Hospital Equipment & SuppliesFiscal year ends December 31
ACCENDRA HEALTH INC/VA/
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$0.22−0.01 (-6.30%)
Close on Oct 19, 2026
- Market cap
- $16.89M
- P/E (TTM)
- –
- Dividend yield
- –
ACCENDRA HEALTH INC/VA/ revenue by segment
By business segment
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient Direct | – | – | – | – | – | $2.72B | $2.68B | $2.65B | $2.61B | $2.58B | $2.55B | $2.51B | – | – |
| Products & Healthcare Services | – | – | – | – | – | $8.00B | $8.02B | $8.01B | $7.92B | $7.84B | $7.78B | $7.72B | – | – |
| Operating income | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient Direct | – | – | – | – | – | $274.42M | $260.16M | $268.11M | $252.62M | $246.89M | $246.86M | $235.31M | – |
| Products & Healthcare Services | – | – | – | – | – | $42.68M | $53.01M | $60.43M | $76.00M | $67.47M | $57.81M | $25.76M | – |
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diabetes | $789.56M | $781.80M | $783.37M | $780.16M | $781.55M | $784.85M | $777.48M | – | – | – | – | – | 29.8% | +1.0% |
| Sleep therapy | $692.07M | $725.12M | $740.05M | $732.80M | $724.16M | $712.77M | $702.95M | – | – | – | – | – | 26.1% | -4.4% |
| Home respiratory therapy | $403.09M | $421.62M | $433.05M | $433.88M | $435.59M | $435.75M | $435.95M | – | – | – | – | – | 15.2% | -7.5% |
| Other | $249.16M | $273.79M | $288.19M | $286.28M | $281.88M | $275.83M | $268.27M | – | – | – | – | – | 9.4% | -11.6% |
| Ostomy | $218.46M | $214.68M | $212.84M | $208.41M | $205.69M | $200.86M | $195.92M | – | – | – | – | – | 8.3% | +6.2% |
| Wound care | $174.64M | $181.26M | $188.51M | $192.01M | $195.48M | $195.82M | $192.41M | – | – | – | – | – | 6.6% | -10.7% |
| Urology | $120.27M | $117.67M | $116.02M | $114.55M | $113.33M | $110.28M | $107.12M | – | – | – | – | – | 4.5% | +6.1% |
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | – | – | – | – | – | $10.49B | $10.46B | $10.41B | $10.27B | $10.16B | $10.06B | $9.95B | – | – |
| International | – | – | – | – | – | $232.20M | $242.94M | $251.62M | $264.76M | $267.45M | $275.29M | $281.85M | – | – |
From the segment and revenue-disaggregation notes of Accendra Health's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.